deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03364439

R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients (FIL_DLCL10)

Prospective, Multicentre Phase II Study With R-CHOP- 14 or R-CHOP-21 & Consolidation PET-Oriented Radiotherapy (RT) in Diffuse Large B Cell Lymphoma (DLBCL) Patients With Low Risk Profile According to Age-adjusted IPI (0 With Bulky or 1)

Sponsor: Fondazione Italiana Linfomi - ETS

Conditions Diffuse Large B Cell Lymphoma
Interventions Treatment plan
Updated 14 times since 2017 Last updated: Feb 15, 2022 Started: Jan 31, 2012 Primary completion: Apr 30, 2018 Completion: Mar 18, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03364439, this PHASE2 trial focuses on Diffuse Large B Cell Lymphoma and remains completed. Sponsored by Fondazione Italiana Linfomi - ETS, it has been updated 14 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Dec 2019 · 6 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jun 2023 · 14 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Jun 2023 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Dec 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. May 2021 — Dec 2021 [monthly]

    Completed PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fondazione Italiana Linfomi - ETS
Data source: Fondazione Italiana Linfomi - ETS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Ancona, Italy , Aviano, Italy , Biella, Italy , Brescia, Italy , Brindisi, Italy , Cagliari, Italy , Castelfranco Veneto, Italy , Como, Italy , Milan, Italy and 7 more locations